Previous studies have reported two major mechanisms of drug resistance in the treatment of advanced ALK-positive NSCLC failure to ALK inhibitors, as follows: ALK-dependent, such as ALK amplification and a secondary mutation of the ALK kinase domain; and ALK-independent, including bypass activation and phenotypic transformation [[3], [4], [5]]. This evidence concerns the gene ALK and non-small cell lung carcinoma.